Morgan Lewis partner Dennis Gucciardo was quoted in a MedTech Dive article about the impact of the coronavirus (COVID-19) on the medtech industry. In the piece, Dennis discussed how companies are navigating the latest guidance from the US Food and Drug Administration (FDA). “I’ve seen FDA do things in this space that I couldn’t believe,” said Dennis. “The fact that FDA is willing to allow a company to distribute a diagnostic test that hasn’t been fully reviewed and approved by FDA is something that is kind of mind-numbing in the larger scheme, but clearly the public benefit outweighs the potential risks.